In a series of 12 patients with inoperable gastric carcinoma who had treatment with a synthetic matrix metalloproteinase inhibitor (Marimastat) for more than one month, six developed a frozen shoulder or a condition resembling Dupuytren’s disease.

This suggests that the matrix metalloproteinases, a family of naturally occurring proteinases, may be involved in the pathogenesis of these two conditions. Our observation opens avenues for further research which could lead to local or systemic therapeutic interventions for frozen shoulder and Dupuytren’s disease.

Received 16 October 1997; Accepted after revision 3 April 1998

The pathogenesis of both Dupuytren’s disease and frozen shoulder is poorly understood, but they have very similar histopathological and immunocytochemical features and associations with other conditions such as hyperlipidaemia and diabetes.

The matrix metalloproteinases (MMPs) are zinc-dependent proteinases which in normal tissues degrade the connective-tissue matrix as part of normal turnover. In gastric carcinoma there is an overexpression of MMPs which leads to an increase in the breakdown of connective tissue and a possible enhancement of tumour invasion.

In a recent phase-II study of the effect of the synthetic broad-spectrum MMP inhibitor, Marimastat (British Biotech Ltd, Oxford, UK), in a dosage of 25 to 100 mg per day, on patients with advanced gastric cancer, it was found that a number developed a frozen shoulder and a hand condition resembling Dupuytren’s disease. This suggests that alterations in MMP activity may be involved in the pathogenesis of these two conditions.

Case reports

Between June 1995 and September 1996 we recruited 24 patients with inoperable, histologically proven primary or recurrent gastric adenocarcinoma into the study. The trial protocol was approved by the Research Ethics Committee. All patients provided witnessed, written informed consent to participate in the study which was conducted in accordance with the European Guidelines on Good Clinical Practice.

Before beginning treatment all patients had routine serum blood tests and a full physical examination. They were reassessed monthly in regard to the response to treatment and the presence of adverse conditions. Once a pattern of shoulder and hand conditions had emerged, we then assessed the musculoskeletal system in all patients both before beginning treatment and at the monthly review.

Of the 24 patients, 12 were judged to have had a favourable response to treatment with Marimastat and continued to receive it beyond the initial one-month assessment period. After four months of treatment three of these 12 patients developed clinical features of Dupuytren’s disease of the hand and frozen shoulder, as defined by Codman in 1934, and another three developed a frozen shoulder alone. In all cases the frozen shoulder was bilateral. Of the three patients with the Dupuytren-type condition two developed contractures with palmar cords and pits involving the little, ring and middle fingers (Fig. 1), and the other palmar nodules only. Unfortunately, no autopsies were performed and therefore no tissue was available for analysis.

The acute symptoms (pain and stiffness) of frozen shoulder improved when treatment with Marimastat was temporarily discontinued, but became worse again when it was recommenced.

Discussion

MMPs are a family of zinc-dependent proteinases the primary function of which is to degrade the extracellular matrix. They are found in normal tissues and regulate the turnover of the connective tissue matrix. The synthesis and
It is postulated that the development of frozen shoulder and the Dupuytren-type condition in our patients was due to a decrease in the MMP:TIMP ratio which caused increased synthesis and deposition of collagen and connective tissue. A decrease in the MMP:TIMP ratio may therefore represent a common pathway in the pathogenesis of Dupuytren’s disease and frozen shoulder. In normal circumstances this ratio may be controlled by a variety of cytokines, growth factors and genetic factors. Although no histopathological analysis was possible and it is not proven that Marimastat caused these hand and shoulder changes, our observation suggests possible therapeutic strategies for these common conditions involving manipulation, either locally or systemically, of the MMP:TIMP activity.

The gastric cancer study was sponsored by British Biotech Pharmaceuticals Ltd, Oxford, UK.

Although none of the authors have received or will receive benefits for personal or professional use from a commercial party related directly or indirectly to the subject of this article, benefits have been or will be received but are directed solely to a research fund, educational institution, or other non-profit institution with which one or more of the authors is associated.

References